Subject
Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference26 articles.
1. U.S. Food Drug Adm. Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tissue-agnostic-drug-development-oncology (2022).
2. Tumour lineage shapes BRCA-mediated phenotypes;Jonsson;Nature,2019
3. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients;van Waalwijk van Doorn-Khosrovani, S. B.;Ann Oncol,2019
4. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer;Kopetz;J Clin Oncol,2015
5. Phase II pilot study of vemurafenib in patients with metastatic BRAF -mutated colorectal cancer;Kopetz;J Clin Oncol,2015